


High Risk Cardiac Surgery

How Can We Prevent Post Cardiectomy Shock?



1

Disclosures

Medtronic - Speakers Board, Paid Consultant
Abbott - Paid Consultant



2

High Risk?





3

Risk and Cardiac Surgery

An Evaluation of Hazards


- Objective
 - STS
 - Frailty
 - Scoring Systems
- Subjective
 - Experience
 - Capacity
 - Personal
 - Institutional
 - Resources



4

Risk Domains In Cardiac Surgery

- Corporeal
 - Deconditioned
 - Obesity
 - One Kidney
 - Eye patch
- Functional
 - EF
 - AI
- Structural
 - Reoperation
 - Patent Mammary
 - Promial RCA
 - Right Dominant




5

An Honest Assessment of Risk

The plural of "anecdote" is not "data"

- Historic Examples
 - Columbus
 - Sound Barrier
 - Pulsatility
- Perverse Incentive (industry, outcomes, effort)
- Correlation vs Causation


10961, 2005, doi:10.1093/ajcp/109.10.414
 Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.
 Hall G, Appleby N, Tranchesi A, White A, Abul E, Durrans MB, Hurrell GL, Traversa A, Demery F, Goss N, Frowd NG, Edwards D, CESAR and CESAR2 Investigators



6

Pre Operative

- Eval
- Nutrition
- Planning
- Team Commitment
- Preop MCS
- Access




7

Coronary Artery Revascularisation


- Selection of patients:
- Several clinical factors play a major role in the decision-making.
 1. The presence of angina,
 2. The severity of heart failure symptoms,
 3. LV dimensions.
 4. The adequacy of target vessels for revascularization and
 5. The extent of jeopardized but still viable myocardium

Significant mortality and morbidity benefit occur after coronary revascularisation when at least 25% of myocardium is viable
Amal F.L. Schinkel et al. JNM 2007



8

STICH (Surgical Treatment of Ischemic Heart Failure)




1212 patients randomized to CABG vs medical therapy


Patients with recent MI, major illness, significant L. Main disease and severe angina excluded

No difference in all cause mortality seen at median 56 months follow-up

17% of patients in medical therapy arm crossed over to surgical arm




9



CABG associated with reduction in cardiovascular death and combined outcome of death or cardiovascular hospitalization

CABG also associated with 30% relative reduction in mortality in "on-treatment" analysis (accounting for patients crossing over within 1st year of study)




10

Recommendations - Revascularization Procedures

Surgical Revascularization for Patients with IHD and HF


Consideration of coronary artery bypass surgery for patients with chronic ischemic cardiomyopathy, LVEF < 35%, graftable coronary arteries and who are otherwise suitable candidates for surgery, irrespective of the presence of angina in order to improve quality of life, cardiovascular death and hospitalization.	Strong Recommendation Moderate Quality Evidence
Consideration of performance of coronary revascularization procedures in patients with chronic heart failure and reduced LV ejection fraction should be undertaken with a medical-surgical team approach with experience and expertise in high risk interventions.	Strong Recommendation Low Quality Evidence



11


STICH Analysis

Improved prognosis with viability



Analysis of 601 patients with viability testing data available


Viability defined as ≥ 11 segments on SPECT or ≥ 5 segments on DSE imaging



12

STICH Analysis

Viability doesn't necessarily predict improved outcomes with surgery vs medical therapy



13

Recommendations - Revascularization Procedures

Surgical Revascularization for Patients with IHD and HF

Consideration of percutaneous coronary angioplasty for patients with heart failure and limiting symptoms of cardiac ischemia, and for whom CABG is not considered appropriate.

Weak Recommendation
Low Quality Evidence



14

Practical Tips

Revascularization Procedures


Surgical Revascularization for Patients with IHD and HF

- In the setting of heart failure, angina and single territory coronary artery disease, PCI may be the treatment of first choice. However, PCI has not been shown to improve outcomes for patients with chronic stable heart failure, irrespective of underlying anatomy.
- Urgent directed culprit vessel angioplasty continues to be the revascularization modality of choice for patients with heart failure and acute coronary syndrome.



15

Decision Regarding Coronary Revascularization in Heart Failure



16

Favors Medical Therapy

- Severe Renal Insufficiency
- Smaller LVESVI (<79 ml/m²)
- Higher LVEF (>28%)
- Single-Vessel Coronary Disease
- Limited Functional Capacity (6MWD <300 meters, KCCQ Physical Ability Score <55)
- More Viable Myocardium
- Ischemic Burden
- Biomarker Level (BNP, STNFR-1)
- Less Viable Myocardium
- Increased MI Risk
- Increased Risk of Sudden Cardiac Death
- Moderate to Severe Mitral Regurgitation
- Preserved Functional Capacity (6MWD ≥300 meters, KCCQ Physical Ability Score >55)
- Lower LVEF (<27%)
- Three-Vessel Coronary Disease
- Larger LVESVI (≥79ml/m²)


Favors CABG + Medical Therapy

17

Valvular dysfunction– Mitral Valve Surgery – Benefits

ACORN TRIAL:


Non randomized, 30 centres, 193 pts, on medical therapy was done to evaluate safety and efficacy of MVR + CorCop cardiac support



18

CTSN: MV Repair vs. Replacement

Trial design: Patients with severe ischemic (functional) mitral regurgitation were randomized to mitral valve repair with mitral annuloplasty (n = 126) vs. mitral valve replacement with chordal sparing (n = 125).



Results

- Mean change in LVESVI from baseline to 1 year: -6.6 ml/m² in the repair group vs. -6.8 ml/m² in the replacement group (p = NS)
- Mortality at 2 years: 19% in the repair group vs. 23% in the replacement group (p = 0.42)
- Moderate or severe mitral regurgitation at 2 years: 59% in the repair group vs. 3.8% in the replacement group (p < 0.001)

Conclusions

- Among individuals with severe ischemic mitral regurgitation, mitral valve repair with mitral annuloplasty vs. mitral valve replacement was associated with similar LV size and mortality
- Patients who underwent mitral valve repair had a marked increase in moderate or severe mitral regurgitation

METHODIST HEART HOSPITAL
A Center of Methodist Health

19

Chronic Primary Mitral Regurgitation: Intervention (cont.)

Recommendations	COR	LOE
MV surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF ≤30% (stage D)	IIb	C
MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation management is questionable	IIb	B

METHODIST HEART HOSPITAL
A Center of Methodist Health

20


BOLLING hypothesis

• there is an *“annular solution for a ventricular problem . . . such that reconstruction of the mitral valve annulus’ geometric abnormality by an undersized ring restores valvular competency, alleviates excessive ventricular workload, improves ventricular geometry and improves ventricular function.”*

METHODIST HEART HOSPITAL
A Center of Methodist Health

21

Algorithm for Mitral Regurgitation



METHODIST HEART HOSPITAL
A Center of Methodist Health

22

Intra Operative

- Access
- Exposure
- Protection
- Techniques
- Pattern Recognition
 - Response
- Hemostasis
- Pump Stewardship

METHODIST HEART HOSPITAL
A Center of Methodist Health

23

Post Operative

- Access
- Nuanced Pain Mgmt
- Pulmonary Toilet
- Goal Derived Weaning Strategy
- Rescue

METHODIST HEART HOSPITAL
A Center of Methodist Health

24

Mechanical Circulatory Support


Multiple Flavors

- Temporary
 - OR
 - ICU
- Durable
 - To Discharge
 - DT
 - BTT

Rescue

Recovery

Bridge



25



Percutaneous LVAD

Impella 2.5, 3.5, 5.5

RECOVER I

Safety and Feasibility for Impella 5.0

- 17 patients in PCCS
- 5 peripheral, 12 direct placement
- Support duration: 3.5 +/- 3.0 days
- Pump flow: 4.2 +/- 0.8 L/min
- Death: 12%
- CVA: 6%
- Aortic insufficiency: 0%
- Bleeding: 17%


26

About the Right Ventricle

- RV Dysfunction
- PAPI
- Medical Optimization
 - Epoprostenol
 - PVR
- Early Intervention Improves Outcome
- Percutaneous vs Open
- In-Line vs Bypass

Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation


Gosin Kang, MD, Richard Ra, MD, and Dipanjan Banerjee, MD, MS

$$PAPi = \frac{(PA_{systolic} - PA_{diastolic})}{RA}$$


27



Summary comparison

Device	Flow	Biocompatibility	Deployment	Fallout	Status	Cost
IABP	1 heart	2 green circles	3 lightning bolts	2 yellow diamonds	2	\$
ECMO	3 hearts	3 green circles	3 lightning bolts	1 yellow diamond	1	\$\$\$\$
Impella	3 hearts	2 green circles	3 lightning bolts	2 yellow diamonds	2	\$\$\$
EC VAD	3 hearts	2 green circles	3 lightning bolts	2 yellow diamonds	1	\$\$



28



MIS meets MCS

29

MCS as Critical Program Support


- Optimal Throughput Model with Minimal Loss
 - Reframing STS Risk
 - Chronic HF to durable MCS
- Rescue
 - Acute Decompensation
 - Witnessed Arrest
 - Post Pump
 - Community Salvage
- Recovery
 - Cath Lab
 - STS Outcomes

30

About the Right Ventricle

- RV Dysfunction
- PAPi
- Medical Optimization
 - Epoprostenol
 - PVR
- Early Intervention Improves Outcome
- Percutaneous vs Open
- In-Line vs Bypass




Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation
Guoan Kang, MD, Richard Hu, MD, and Dhanraj Banerjee, MD, PhD


$$PAPi = \frac{(PA_{systolic} - PA_{diastolic})}{RA}$$

PAPi <1.85 is sensitive and specific for RVF after LVAD

Journal of Thoracic and Cardiovascular Surgery, Volume 152, Number 5, October 2017



31



32